Zongan A. Liang

CN 
CN 

Overview

Zongan Liang practices practicing medicine in China.

Their clinical expertise encompasses Pneumonia, COVID-19, Cor Pulmonale, Acute Respiratory Distress Syndrome (ARDS), and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 2 clinical trials.

Locations

China
Other Locations
Chengdu, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Enrollment Status: Unknown
Publish Date: April 20, 2018
Intervention Type: Drug
Study Drug: Ulinastatin
Study Phase: Phase 2
View 1 Less Clinical Trial

60 Total Publications

Inhalable TFRC-Targeted Extracellular Vesicles Delivery of siTGF-β1 Alleviates Pulmonary Fibrosis via Dual Inhibition of Ferroptosis and Fibroblast Activation.
Inhalable TFRC-Targeted Extracellular Vesicles Delivery of siTGF-β1 Alleviates Pulmonary Fibrosis via Dual Inhibition of Ferroptosis and Fibroblast Activation.
Journal: International journal of nanomedicine
Published: September 16, 2025

Frequently Asked Questions about Zongan A. Liang

Is Zongan A. Liang a top-rated expert for Pneumonia?

MediFind is an objective health platform that identifies experts based on real-world data. Zongan A. Liang is classified as an Experienced expert for Pneumonia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zongan A. Liang participate in research or clinical trials?

Yes. Zongan A. Liang has published 60 articles and abstracts on conditions like Pneumonia. You can view a list of Zongan A. Liang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liang's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile